A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Astellas EVP Okamura to Become CEO in April
February 6, 2023
-
BUSINESS Mitsubishi Chemical Calls It Quit for Medicago, COVID Jab
February 6, 2023
-
BUSINESS Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
February 3, 2023
-
REGULATORY Chuikyo OKs Use of Multiple Comparators to Price Xocova, Upping of Reduction Cap Mooted for Re-Pricing
February 2, 2023
-
BUSINESS Daiichi Sankyo Taps CFO Okuzawa as New President, Set to Continue ADC Drive
February 1, 2023
-
BUSINESS Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
January 31, 2023
-
BUSINESS Lecanemab Earns Priority Review in Japan, Eisai Aims for Approval by Year-End
January 31, 2023
-
REGULATORY Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
January 30, 2023
-
REGULATORY It’s Official: Japan to Downgrade COVID-19 Severity Status on May 8
January 30, 2023
-
REGULATORY Experts Doubt Necessity of Policy Intervention for LLP-Dependent Companies
January 27, 2023
-
REGULATORY Japan to Lower COVID-19 Severity Status on May 8
January 27, 2023
-
REGULATORY Chuikyo Begins Xocova Price Debate under Mega Seller Rule, Weighs Quicker Re-Pricing
January 26, 2023
-
ORGANIZATION PhRMA Poised to Issue 2024 Reform Proposal in Next Few Months: New Japan Chief
January 25, 2023
-
REGULATORY Xocova Might Trigger Mega Seller Price Control Rule for First Time
January 24, 2023
-
REGULATORY Setting “Presumed Efficacy” Criteria Would Be Difficult; Xocova Decision Reasonable: PMDA Chief
January 23, 2023
-
REGULATORY Japan to Downgrade COVID-19 Status to Seasonal Flu Level This Spring
January 23, 2023
-
BUSINESS Opdivo Outdistances Keytruda in 2022 with Sales Up 30 Billion Yen YOY: Encise
January 20, 2023
-
REGULATORY Former Minister Nemoto to Initiate Debates on Pharma Policies by Young Lawmakers
January 19, 2023
-
BUSINESS Ex-Sandoz Japan Chief Tapped to Spearhead Nichi-Iko Turnaround
January 18, 2023
-
REGULATORY Ex-Minister Tamura Hightlights Need for Rewarding Innovation towards FY2024 Drug Reform
January 17, 2023
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…